TRANSTHERA-B (02617): First Patient Dosed in Confirmatory Phase III Trial of Tinengotinib Monotherapy for Advanced Cholangiocarcinoma

Stock News

04/17

TRANSTHERA-B (02617) announced that the first patient has been dosed in a confirmatory Phase III clinical study evaluating its core product, Tinengotinib (TT-00420), as a monotherapy for patients with advanced cholangiocarcinoma. This trial is a randomized, controlled, open-label, multicenter Phase III study conducted in China. It is designed to assess the efficacy and safety of Tinengotinib compared to chemotherapy in patients with surgically unresectable, advanced or metastatic intrahepatic cholangiocarcinoma. Eligible patients have experienced recurrence or progression following prior first-line systemic therapy and carry FGFR2 fusions, rearrangements, or mutations.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1176775881"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1176775881\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1176775881?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-17 18:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176775881","market":"sg","top_or_hot":-1,"title":"TRANSTHERA-B (02617): First Patient Dosed in Confirmatory Phase III Trial of Tinengotinib Monotherapy for Advanced Cholangiocarcinoma","media":"Stock News","content":"<p>TRANSTHERA-B (02617) announced that the first patient has been dosed in a confirmatory Phase III clinical study evaluating its core product, Tinengotinib (TT-00420), as a monotherapy for patients with advanced cholangiocarcinoma. This trial is a randomized, controlled, open-label, multicenter Phase III study conducted in China. It is designed to assess the efficacy and safety of Tinengotinib compared to chemotherapy in patients with surgically unresectable, advanced or metastatic intrahepatic cholangiocarcinoma. Eligible patients have experienced recurrence or progression following prior first-line systemic therapy and carry FGFR2 fusions, rearrangements, or mutations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TRANSTHERA-B (02617): First Patient Dosed in Confirmatory Phase III Trial of Tinengotinib Monotherapy for Advanced Cholangiocarcinoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTRANSTHERA-B (02617): First Patient Dosed in Confirmatory Phase III Trial of Tinengotinib Monotherapy for Advanced Cholangiocarcinoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-17 18:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TRANSTHERA-B (02617) announced that the first patient has been dosed in a confirmatory Phase III clinical study evaluating its core product, Tinengotinib (TT-00420), as a monotherapy for patients with advanced cholangiocarcinoma. This trial is a randomized, controlled, open-label, multicenter Phase III study conducted in China. It is designed to assess the efficacy and safety of Tinengotinib compared to chemotherapy in patients with surgically unresectable, advanced or metastatic intrahepatic cholangiocarcinoma. Eligible patients have experienced recurrence or progression following prior first-line systemic therapy and carry FGFR2 fusions, rearrangements, or mutations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4134","symbol_name":"信息科技咨询与其它服务","start_time":0,"source_url":"","article_id":"1176775881","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176775881","pubTimestamp":1776422683,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"TRANSTHERA-B (02617) announced that the first patient has been dosed in a confirmatory Phase III clinical study evaluating its core product, Tinengotinib (TT-00420), as a monotherapy for patients...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4134":"信息科技咨询与其它服务","02617":"药捷安康-B","III":"信息服务","BK1161":"生物科技"},"translate_title":"Tranthera-B（02617）：替能替尼单药治疗晚期胆管癌的确证性III期试验中首例给药患者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02617":1,"III":1},"content_text":"TRANSTHERA-B (02617) announced that the first patient has been dosed in a confirmatory Phase III clinical study evaluating its core product, Tinengotinib (TT-00420), as a monotherapy for patients with advanced cholangiocarcinoma. This trial is a randomized, controlled, open-label, multicenter Phase III study conducted in China. It is designed to assess the efficacy and safety of Tinengotinib compared to chemotherapy in patients with surgically unresectable, advanced or metastatic intrahepatic cholangiocarcinoma. Eligible patients have experienced recurrence or progression following prior first-line systemic therapy and carry FGFR2 fusions, rearrangements, or mutations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}